VOLUME 26 , ISSUE 9 ( September, 2022 ) > List of Articles
Jayaraj Mymbilly Balakrishnan, Freston Marc Sirur, Nayan Prakash, Rachana Bhat, William Wilson, Bharath Angadi, Sanjan Asanar
Keywords : Barrier enclosure, Coronavirus disease-2019, Emergency department, Healthcare workers, India, Resource-limited settings, Transmission of infection
Citation Information : Balakrishnan JM, Sirur FM, Prakash N, Bhat R, Wilson W, Angadi B, Asanar S. Portable Biosafety Barrier Innovations to Limit Transmissibility of Infectious Diseases during Patient Care in Resource-limited Settings during the COVID-19 Pandemic. Indian J Crit Care Med 2022; 26 (9):1036-1038.
DOI: 10.5005/jp-journals-10071-24307
License: CC BY-NC 4.0
Published Online: 31-08-2022
Copyright Statement: Copyright © 2022; The Author(s).
Background: The coronavirus disease-2019 (COVID-19) pandemic has brought about a change in healthcare practices that are likely to persist into the foreseeable future. In particular, is the exposure risk to the healthcare practitioners in the emergency department (ED) and the intensive care units. Mitigating this issue in a low-resource setting remains challenging, and in particular, in developing nations such as India, where ED patient flows can overwhelm a system and its human resources, breaking down processes and infecting healthcare workers (HCWs). Technique: To tackle this and the possible lack of appropriate personal protective equipment (PPE), we designed and built biosafety barrier devices using local resources for use in patient stabilization, transport, and continued care in the ED or the intensive care units. Results: Four biosafety devices bio-safe levels 1 and 2, ultra-ductile portable interface of interventions in infections, and tented transport trolley for transmissibility (4T) were tested for the feasibility of usage for patient care during the pandemic with simulation. Conclusion: We anticipate that with time it may be common practice for in situ isolation of patients in the emergency departments with a suspicion of an infectious disease. With the proof of concept, simulation, hospital infection control committee (HICC) approval, and trial run, we look to close the gaps that exist in these initial innovations.